Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Saudi Journal of AnaesthesiaOpen Access

Sublingual dexmedetomidine: An old drug with a new route for agitation

View Full Paper
Ask AI
Bookmark
Share

Authors

KCKonica ChittoriaASAnkur SharmaNKNikhil Kothari

Discussion

Loading...

Member takes

Overview

Observational analysis reveals safety and efficacy of sublingual dexmedetomidine in agitation treatment, highlighting its potential benefits.

Key Points

  • Sublingual dexmedetomidine shows promise as a sedative agent for patients with agitation.
  • FDA approval establishes it as the first sedative specifically indicated for agitation in mental health conditions.
  • The article discusses both benefits and adverse effects related to this novel delivery method.
  • Indications include schizophrenia and bipolar disorders, emphasizing its therapeutic potential.

Cite This Study

Chittoria et al. (2025) studied this question.

synapsesocial.com/papers/68c183fe9b7b07f3a06101cfhttps://doi.org/10.4103/sja.sja_361_25
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Dexmedetomidine: A Novel Sedative-Analgesic Agent2001 · 861 citations
  2. 2Agitation Onset, Frequency, and Associated Temporal Factors in Critically Ill Adults2014 · 32 citations
  3. 3Sublingual dexmedetomidine (BXCL501) reduces opioid withdrawal symptoms: findings from a multi-site, phase 1b/2, randomized, double-blind, placebo-controlled trial2023 · 12 citations
  4. 4Sublingual Dexmedetomidine for the Treatment of Agitation in Patients with Schizophrenia and Bipolar Disorder2023 · 26 citations
  5. 5Intranasal versus sublingual route of dexmedetomidine sedation in paediatric dentistry: A randomized controlled clinical trial2021 · 14 citations